Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CATXBullishIndustry Newsnews

High materiality8/10

Perspective Therapeutics to Present 212Pb VMT01 Data at SITC 2026

Oct 2, 2026, 12:08 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive interim signals in early-stage melanoma therapy, plus a forthcoming SITC catalyst; small patient samples limit conviction, but a durable signal could trigger a rerating.

AI summary

What happened, with direct paths to the underlying reporting

Perspective Therapeutics announced SITC 2026 presentation for [212Pb]VMT01 targeting MC1R-positive melanoma. Interim ASCO data reported two responders among seven in the 3.0 mCi monotherapy cohort, with 86% achieving SD/PR and no dose-limiting toxicities. The upcoming SITC abstract could catalyze investor attention, contingent on durability and safety signals.

SITC to present [212Pb]VMT01 melanoma data at SITC 2026.
ASCO interim: median 4 prior lines; 86% SD/PR in 3.0 mCi cohort; no DLTs.
Targets MC1R-expressing melanoma with 212Pb; theranostic approach; pipeline assets.
Near-term catalyst: SITC abstract acceptance; data release early November.
Nivolumab combo explored; could expand addressable melanoma patients.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.